Zhou M, Xu M, Zhang X, Xing X, Li Y, Wang G
PLoS One. 2025; 20(2):e0318368.
PMID: 39913435
PMC: 11801531.
DOI: 10.1371/journal.pone.0318368.
Schuhknecht L, Ortmayr K, Janes J, Blasi M, Panoussis E, Bors S
Nat Biotechnol. 2025; .
PMID: 39875672
DOI: 10.1038/s41587-024-02524-5.
Feng C, Cheng J, Sun M, Qiao C, Feng Q, Fang N
Front Pharmacol. 2025; 15():1522787.
PMID: 39840098
PMC: 11747269.
DOI: 10.3389/fphar.2024.1522787.
Chen J, Lin A, Jiang A, Qi C, Liu Z, Cheng Q
NPJ Digit Med. 2025; 8(1):44.
PMID: 39828791
PMC: 11743742.
DOI: 10.1038/s41746-025-01435-2.
Wang W, Fan X, Wei X, Chai W, Li F, Gao K
Front Pharmacol. 2024; 15:1466208.
PMID: 39717556
PMC: 11663646.
DOI: 10.3389/fphar.2024.1466208.
Simulate Scientific Reasoning with Multiple Large Language Models: An Application to Alzheimer's Disease Combinatorial Therapy.
Xu Q, Liu X, Jiang X, Kim Y
medRxiv. 2024; .
PMID: 39711724
PMC: 11661384.
DOI: 10.1101/2024.12.10.24318800.
Knowledge graph embeddings in the biomedical domain: are they useful? A look at link prediction, rule learning, and downstream polypharmacy tasks.
Pradipta Gema A, Grabarczyk D, De Wulf W, Borole P, Alfaro J, Minervini P
Bioinform Adv. 2024; 4(1):vbae097.
PMID: 39506988
PMC: 11538020.
DOI: 10.1093/bioadv/vbae097.
Optimal linear ensemble of binary classifiers.
Ahsen M, Vogel R, Stolovitzky G
Bioinform Adv. 2024; 4(1):vbae093.
PMID: 39011276
PMC: 11249386.
DOI: 10.1093/bioadv/vbae093.
MPHGCL-DDI: Meta-Path-Based Heterogeneous Graph Contrastive Learning for Drug-Drug Interaction Prediction.
Hu B, Yu Z, Li M
Molecules. 2024; 29(11).
PMID: 38893359
PMC: 11173658.
DOI: 10.3390/molecules29112483.
DRGATAN: Directed relation graph attention aware network for asymmetric drug-drug interaction prediction.
Zhang D, Wang Z, Zhao D, Li J
iScience. 2024; 27(6):109943.
PMID: 38868194
PMC: 11167430.
DOI: 10.1016/j.isci.2024.109943.
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S
Sci Adv. 2024; 10(21):eadj1564.
PMID: 38781347
PMC: 11114247.
DOI: 10.1126/sciadv.adj1564.
From cell lines to cancer patients: personalized drug synergy prediction.
Kuru H, Cicek A, Tastan O
Bioinformatics. 2024; 40(5).
PMID: 38718189
PMC: 11215552.
DOI: 10.1093/bioinformatics/btae134.
Polypharmacy and precision medicine.
Fujita K, Masnoon N, Mach J, Kouladjian Odonnell L, Hilmer S
Camb Prism Precis Med. 2024; 1:e22.
PMID: 38550925
PMC: 10953761.
DOI: 10.1017/pcm.2023.10.
Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies.
April-Monn S, Kirchner P, Detjen K, Brautigam K, Trippel M, Grob T
NPJ Precis Oncol. 2024; 8(1):59.
PMID: 38429350
PMC: 10907580.
DOI: 10.1038/s41698-024-00549-2.
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
Abd El-Hafeez T, Shams M, Elshaier Y, Farghaly H, Hassanien A
Sci Rep. 2024; 14(1):2428.
PMID: 38287066
PMC: 10825182.
DOI: 10.1038/s41598-024-52814-w.
Antimalarial Drug Combination Predictions Using the Machine Learning Synergy Predictor (MLSyPred©) tool.
Roche-Lima A, Rosado-Quinones A, Feliu-Maldonado R, Figueroa-Gispert M, Diaz-Rivera J, Diaz-Gonzalez R
Acta Parasitol. 2024; 69(1):415-425.
PMID: 38165555
PMC: 11001753.
DOI: 10.1007/s11686-023-00765-z.
In vitro and in vivo approaches to assess atherosclerosis following exposure to low-dose mixtures of arsenic and cadmium.
Subramaniam N, Gagnon N, Makhani K, Kukolj N, Mouradian M, Giles B
Toxicol Appl Pharmacol. 2023; 481:116763.
PMID: 37980961
PMC: 11414205.
DOI: 10.1016/j.taap.2023.116763.
Combined Treatment of Dendrosomal-Curcumin and Daunorubicin Synergistically Inhibit Cell Proliferation, Migration and Induce Apoptosis in A549 Lung Cancer Cells.
Eslami S, Jafari D, Ghotaslou A, Amoupour M, Kojabad A, Jafari R
Adv Pharm Bull. 2023; 13(3):539-550.
PMID: 37646049
PMC: 10460814.
DOI: 10.34172/apb.2023.050.
Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)--Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer.
Shin Y, Choi J, Shin D, Lee J
Int J Nanomedicine. 2023; 18:2209-2223.
PMID: 37152471
PMC: 10162106.
DOI: 10.2147/IJN.S394712.
Predicting anti-cancer drug combination responses with a temporal cell state network model.
Sarmah D, Meredith W, Weber I, Price M, Birtwistle M
PLoS Comput Biol. 2023; 19(5):e1011082.
PMID: 37126527
PMC: 10174488.
DOI: 10.1371/journal.pcbi.1011082.